ACD856

DRUG3 trials

Sponsors

AlzeCure Pharma

Conditions

Alzheimer DiseaseCognition Disorder

Early Phase 1

Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856

CompletedNCT05783830

AlzeCure PharmaAlzheimer Disease, Cognition Disorder

Start: 2020-01-13End: 2020-04-18Updated: 2023-03-24

Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856

CompletedNCT05077501

AlzeCure PharmaAlzheimer Disease, Cognition Disorder

Start: 2021-09-29End: 2022-05-23Updated: 2022-07-20

Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

CompletedNCT05077631

AlzeCure PharmaAlzheimer Disease, Cognition Disorder

Start: 2021-02-15End: 2022-02-22Updated: 2022-07-20

Related Papers

ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics.

2024-02-142 citations